115 related articles for article (PubMed ID: 38061213)
1. Adjuvant chemotherapy in patients with clinically node-negative but pathologically node-positive rectal cancer in the Netherlands: A retrospective analysis.
Kwakman JJM; Bond MJG; Demichelis RM; Koopman M; Hompes R; Elferink MAG; Punt CJA
Eur J Cancer; 2024 Jan; 197():113466. PubMed ID: 38061213
[TBL] [Abstract][Full Text] [Related]
2. Oncologic benefit of adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and curative surgery with selective lateral pelvic lymph node dissection: An international retrospective cohort study.
Fukui Y; Hida K; Hoshino N; Song SH; Park SY; Choi GS; Maeda Y; Matoba S; Kuroyanagi H; Bae SU; Jeong WK; Baek SK; Sakai Y
Eur J Surg Oncol; 2022 Jul; 48(7):1631-1637. PubMed ID: 35153105
[TBL] [Abstract][Full Text] [Related]
3. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.
Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB
Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial.
Breugom AJ; van Gijn W; Muller EW; Berglund Å; van den Broek CBM; Fokstuen T; Gelderblom H; Kapiteijn E; Leer JWH; Marijnen CAM; Martijn H; Meershoek-Klein Kranenbarg E; Nagtegaal ID; Påhlman L; Punt CJA; Putter H; Roodvoets AGH; Rutten HJT; Steup WH; Glimelius B; van de Velde CJH
Ann Oncol; 2015 Apr; 26(4):696-701. PubMed ID: 25480874
[TBL] [Abstract][Full Text] [Related]
5. Local recurrences in western low rectal cancer patients treated with or without lateral lymph node dissection after neoadjuvant (chemo)radiotherapy: An international multi-centre comparative study.
Kroon HM; Malakorn S; Dudi-Venkata NN; Bedrikovetski S; Liu J; Kenyon-Smith T; Bednarski BK; Ogura A; van de Velde CJH; Rutten HJT; Beets GL; Thomas ML; Kusters M; Chang GJ; Sammour T
Eur J Surg Oncol; 2021 Sep; 47(9):2441-2449. PubMed ID: 34120810
[TBL] [Abstract][Full Text] [Related]
6. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
[TBL] [Abstract][Full Text] [Related]
7. Is adjuvant chemotherapy necessary for patients with pathological complete response after neoadjuvant chemoradiotherapy and radical surgery in locally advanced rectal cancer? Long-term analysis of 40 ypCR patients at a single center.
Zhou J; Qiu H; Lin G; Xiao Y; Wu B; Wu W; Sun X; Lu J; Zhang G; Xu L; Liu Y
Int J Colorectal Dis; 2016 Jun; 31(6):1163-8. PubMed ID: 27044403
[TBL] [Abstract][Full Text] [Related]
8. Selective lateral lymph node dissection after neoadjuvant chemoradiotherapy in rectal cancer.
Chen JN; Liu Z; Wang ZJ; Mei SW; Shen HY; Li J; Pei W; Wang Z; Wang XS; Yu J; Liu Q
World J Gastroenterol; 2020 Jun; 26(21):2877-2888. PubMed ID: 32550762
[TBL] [Abstract][Full Text] [Related]
9. Recurrence rates and prognostic factors in ypN0 rectal cancer after neoadjuvant chemoradiation and total mesorectal excision.
Govindarajan A; Reidy D; Weiser MR; Paty PB; Temple LK; Guillem JG; Saltz LB; Wong WD; Nash GM
Ann Surg Oncol; 2011 Dec; 18(13):3666-72. PubMed ID: 21590450
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer to transform effectively EMVI and MRF from positive to negative: results of a long-term single center phase 2 clinical trial.
Zhang W; Zhou H; Jiang J; Zhu Y; Zou S; Jiang L; Tang Y; Liang J; Sun Y; Jiang Z; Qu W; Li Y; Zhou A
BMC Cancer; 2023 Jun; 23(1):592. PubMed ID: 37370032
[TBL] [Abstract][Full Text] [Related]
11. ADJUVANT CHEMOTHERAPY IN LOCALLY ADVANCED RECTAL CANCER: DECIDING ON THE OPTIMAL STRATEGY.
de Torres-Olombrada MV; Juez-Martel I; Rodríguez-Caravaca G; Duran-Poveda M
Rev Invest Clin; 2020; 72(2):88-94. PubMed ID: 32284624
[TBL] [Abstract][Full Text] [Related]
12. The potential benefit of adjuvant chemotherapy in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy is not predicted by tumor regression grade.
Bohlok A; Hendlisz A; Bouazza F; Galdon MG; Van de Stadt J; Moretti L; El Nakadi I; Liberale G
Int J Colorectal Dis; 2018 Oct; 33(10):1383-1391. PubMed ID: 29984385
[TBL] [Abstract][Full Text] [Related]
13. Lateral Nodal Features on Restaging Magnetic Resonance Imaging Associated With Lateral Local Recurrence in Low Rectal Cancer After Neoadjuvant Chemoradiotherapy or Radiotherapy.
Ogura A; Konishi T; Beets GL; Cunningham C; Garcia-Aguilar J; Iversen H; Toda S; Lee IK; Lee HX; Uehara K; Lee P; Putter H; van de Velde CJH; Rutten HJT; Tuynman JB; Kusters M;
JAMA Surg; 2019 Sep; 154(9):e192172. PubMed ID: 31268504
[TBL] [Abstract][Full Text] [Related]
14. The effect of adjuvant chemotherapy on survival and recurrence after curative rectal cancer surgery in patients who are histologically node negative after neoadjuvant chemoradiotherapy.
Baird DLH; Denost Q; Simillis C; Pellino G; Rasheed S; Kontovounisios C; Tekkis PP; Rullier E
Colorectal Dis; 2017 Nov; 19(11):980-986. PubMed ID: 28493401
[TBL] [Abstract][Full Text] [Related]
15. [A single center retrospective study on surgical efficacy of T3NxM0 middle-low rectal cancer without neoadjuvant therapy].
Liu P; Lou Z; Mei Z; Gao X; Hao L; Liu L; Gong H; Meng R; Yu E; Wang H; Wang H; Zhang W
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):66-72. PubMed ID: 30703796
[TBL] [Abstract][Full Text] [Related]
16. Is adjuvant chemotherapy really needed after curative surgery for rectal cancer patients who are node-negative after neoadjuvant chemoradiotherapy?
Kiran RP; Kirat HT; Burgess AN; Nisar PJ; Kalady MF; Lavery IC
Ann Surg Oncol; 2012 Apr; 19(4):1206-12. PubMed ID: 21935748
[TBL] [Abstract][Full Text] [Related]
17. Treatment of clinical T1 rectal cancer in the Netherlands; a population-based overview of clinical practice.
Verseveld M; Verver D; Noordman BJ; Pouwels S; Elferink MAG; de Graaf EJR; Verhoef C; Doornebosch PG; de Wilt JHW
Eur J Surg Oncol; 2022 May; 48(5):1153-1160. PubMed ID: 34799230
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant Management of Pathologic Node-Positive Disease After Definitive Surgery for Clinical T1-2 N0 Rectal Cancer.
Polamraju P; Haque W; Verma V; Wiederhold L; Hatch S; Butler EB; Teh BS
Clin Colorectal Cancer; 2018 Sep; 17(3):e519-e530. PubMed ID: 29753642
[TBL] [Abstract][Full Text] [Related]
19. Impact of Lymph Node Ratio on Oncologic Outcomes in ypStage III Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy followed by Total Mesorectal Excision, and Postoperative Adjuvant Chemotherapy.
Koo T; Song C; Kim JS; Kim K; Chie EK; Kang SB; Lee KW; Kim JH; Jeong SY; Kim TY
PLoS One; 2015; 10(9):e0138728. PubMed ID: 26381522
[TBL] [Abstract][Full Text] [Related]
20. Improved Survival After Adjuvant Therapy in Locally Advanced Rectal Cancer Patients With Pathologic Complete Response.
Lai SH; Vogel JD; Vemuru S; Messersmith W; Lieu C; McCarter MD; Birnbaum E; Chapman BC
Dis Colon Rectum; 2023 Jul; 66(7):983-993. PubMed ID: 36602514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
